MARAVAI LIFESCIENCES HOLDINGS, INC. — fact timeline

MARAVAI LIFESCIENCES HOLDINGS, INC. incurred revolving credit of $30.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.

“On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).”

MARAVAI LIFESCIENCES HOLDINGS, INC. incurred term loan of $150.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.

“On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).”

MARAVAI LIFESCIENCES HOLDINGS, INC. terminated Prior Credit Agreement with Morgan Stanley Senior Funding, Inc. (effective 2026-06-02).

“On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder.”

MARAVAI LIFESCIENCES HOLDINGS, INC. entered into New Credit Agreement with certain lenders and issuing banks valued at $150.0 million term loan facility and a $30.0 million revolving credit facility (effective 2026-06-02).

“On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent.”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. at the 2026-05-26 meeting.

“Proposal No. 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company’s shareholders approved, on a non-binding and advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 200,054,156.49 2,457,403.00 312,439.00 33,258,969.51”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-05-26 meeting.

“Proposal No. 2: Proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified by the Company’s shareholders. Votes For Votes Against Abstentions 234,492,897.00 1,246,939.00 343,132.00”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Election of directors. at the 2026-05-26 meeting.

“Proposal No. 1: Election of directors. The Company’s shareholders elected the following nominees for director to serve for three-year terms expiring at the Company’s 2029 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until his or her earlier death, resignation or removal. Nominee Votes For Votes Withheld Broker Non-Votes Bernd Brust 182,998,545.00 19,825,453.49 33,258,969.51 Gregory T. Lucier 179,514,826.00 23,309,172.49 33,258,969.51 Luke Marker 182,239,834.00 20,584,164.49 33,258,969.51”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported first quarter ended March 31, 2026 results: revenue $65.8 million, net income $(6.4) million. Guidance raised.

“Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: • Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million;”

MARAVAI LIFESCIENCES HOLDINGS, INC. announced a restructuring with charges of $8.0 million to $9.0 million affecting the Company's workforce (approximately 25% of the Company's workforce).

“On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incur restructuring and related costs in the range of $8.0 million to $9.0 million, consisting primarily of employee severance and benefits costs, the majority of which the Company expects to recognize in the second half of 2025.”

MARAVAI LIFESCIENCES HOLDINGS, INC. dismissed Ernst & Young LLP as its auditor.

“In addition, on the Approval Date, the Audit Committee approved the dismissal of Ernst & Young LLP (“ EY ”) as the Company’s independent registered public accounting firm.”

MARAVAI LIFESCIENCES HOLDINGS, INC. engaged Deloitte & Touche LLP as its auditor.

“(the “ Company ”) approved the appointment of Deloitte & Touche LLP (“ Deloitte ”) as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, effective immediately.”

William E. Martin, III resigned as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“Mr. Martin resigned from the Board”

Bernd Brust was appointed as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“Mr. Brust was appointed as a member of the Board”

Andrew Burch departed as President, Nucleic Acid Production at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On January 2, 2025, the Company notified Andrew Burch, President, Nucleic Acid Production, that it was eliminating his position in order to flatten the organizational structure of its leadership team. As a result, Mr. Burch’s last day of employment with the Company will be January 16, 2025.”

William 'Trey' Martin, III was appointed as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“appointed William "Trey" Martin, III to the Board effective as of July 31, 2024, to fill the vacancy on the Board created by Anat Ashkenazi’s previously-reported resignation.”

Anat Ashkenazi resigned as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On June 10, 2024, Anat Ashkenazi, a director of Maravai LifeSciences Holdings, Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) that she plans to resign from the Board effective as of July 31, 2024, in consideration of the time commitments associated with her pending appointment as Chief Financial Officer of Alphabet Inc.”

MARAVAI LIFESCIENCES HOLDINGS, INC. updated its first quarter ended March 31, 2024 guidance (reaffirmed).

“On May 8, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the first quarter of 2024.”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2024 results: revenue $265.0 million to $285.0 million. Guidance initiated.

“Introduced full year 2024 revenue guidance range of $265.0 million to $285.0 million.”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Full Year 2023 results: revenue Annual revenue of $288.9 million, net income Net loss of $(138.4) million.

“Annual revenue of $288.9 million, Net loss of $(138.4) million, and Adjusted EBITDA margin of 23%;”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported Fourth Quarter 2023 results: revenue Quarterly revenue of $74.1 million, net income Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets.

“Quarterly revenue of $74.1 million, Net loss of $(110.0) million, following a valuation adjustment to certain deferred tax assets, and Adjusted EBITDA margin of 28%;”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported financial results for for the fourth quarter ended December 31, 2023.

“On February 22, 2024, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the fourth quarter of 2023.”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported the third quarter ended September 30, 2023 results: revenue $66.9 million, net income Net loss of $(15.1) million. Guidance reaffirmed.

“reported financial results for the third quarter ended September 30, 2023, together with other business updates. Recent highlights include: Financial: • Quarterly revenue of $66.9 million, Net loss of $(15.1) million, and Adjusted EBITDA margin of 18%; and • Updated financial guidance for the full year 2023 to a revenue range of $275.0 million to $285.0 million.”

MARAVAI LIFESCIENCES HOLDINGS, INC. updated its the full year 2023 guidance (lowered).

“we are taking a more conservative view of our financial guidance for the full year”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $147.9 million, net income Net loss ... $(13.3) million. Guidance reaffirmed.

“Revenue for the six months ended June 30, 2023 was $147.9 million, representing a 70% decrease over the same period in the prior year”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: revenue $68.9 million, net income Net loss of $(11.9) million. Guidance reaffirmed.

“innovators, today reported financial results for the second quarter ended June 30, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $68.9 million, Net loss of $(11.9) million, and Adjusted EBITDA margin of 13.2%; • Completed planned leadership transition with the appointment of Trey Martin as CEO effective July 27, 2023,”

Carl W. Hull changed role as Executive Chairman at MARAVAI LIFESCIENCES HOLDINGS, INC..

“Concurrently with the appointment of Mr. Martin as CEO, Carl W. Hull ceased to serve as interim CEO of the Company.”

William 'Trey' Martin, III was appointed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On July 27, 2023, William “Trey” Martin, III assumed the role of Chief Executive Officer (“CEO”) of Maravai LifeSciences Holdings, Inc.”

John DeFord was appointed as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On July 20, 2023, the Board appointed John DeFord, Ph.D. to the Board, effective as of such date (the “Appointment Date”), to fill the vacancy on the Board created by Mr. Hance’s resignation.”

Robert B. Hance resigned as Director at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On July 19, 2023, Robert B. Hance, a director of Maravai LifeSciences Holdings, Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) of his resignation from the Board, to be effective as of such date.”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2023-05-18 meeting.

“Proposal No. 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's Proxy Statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 221,869,456 8,907,696 27,642 4,060,647”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-18 meeting.

“Proposal No. 2: Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was ratified. Votes For Votes Against Abstentions 234,840,684 15,103 9,654”

MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Election of directors at the 2023-05-18 meeting.

“Proposal No. 1: Election of directors. The Company’s shareholders elected the following nominees for director to serve as Class III directors for a three-year term expiring at the Company’s 2026 annual meeting of shareholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Anat Ashkenazi 186,578,234 44,226,560 4,060,647 Gregory T. Lucier 186,046,648 44,758,145 4,060,648 Luke Marker 183,198,145 47,606,648 4,060,648”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: revenue $79.0 million, net income $(1.3) million.

“Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $79.0 million, Net loss of $(1.3) million, and Adjusted EBITDA margins of 30.1%;”

Andrew Burch was appointed as Executive Vice President and General Manager of the Company’s Nucleic Acid Products Operating Division at MARAVAI LIFESCIENCES HOLDINGS, INC..

“Andrew Burch, previously an executive at Thermo Fisher Scientific, has joined the Company and will assume the role of Executive Vice President and General Manager of the Company’s Nucleic Acid Products Operating Division following Mr. Neel’s departure on March 31st.”

Brian Neel resigned as Chief Operating Officer, Nucleic Acid Production at MARAVAI LIFESCIENCES HOLDINGS, INC..

“Brian Neel, Chief Operating Officer, Nucleic Acid Production, of Maravai LifeSciences Holdings, Inc. (the “Company”) notified the Company of his decision to resign to pursue other interests effective March 31, 2023.”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year 2023 results: revenue $420.0 million to $460.0 million. Guidance initiated.

“Introduced 2023 revenue guidance range of $420.0 million to $460.0 million”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year ended December 31, 2022 results: revenue $883.0 million, net income $490.7 million, EPS $1.80.

“Annual revenue of $883.0 million, Net income of $490.7 million and Adjusted fully diluted EPS of $1.80”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported fourth quarter ended December 31, 2022 results: revenue $204.7 million, net income $87.4 million, EPS $0.35.

“Quarterly revenue of $204.7 million, Net income of $87.4 million, and Adjusted fully diluted earnings per share (EPS) of $0.35”

William "Trey" Martin, III changed role as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

“its expectation that Martin will assume the role of Chief Executive Officer of the Company effective July 27, 2023”

William "Trey" Martin, III was appointed as President of Biologics Safety Testing Segment at MARAVAI LIFESCIENCES HOLDINGS, INC..

“William “Trey” Martin, III to serve as President of Maravai’s Biologics Safety Testing Segment beginning December 5, 2022”

MARAVAI LIFESCIENCES HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $191.3 million, net income $99.7 million.

“Quarterly revenue of $191.3 million, Net income of $99.7 million, and Adjusted EBITDA margins of 69%;”

Carl Hull was appointed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

“the Board of Directors (the “Board”) of the Company has appointed Carl Hull, Executive Chairman of the Board, to serve as interim Chief Executive Officer to maintain continuity of the day-to-day operations and draw upon his extensive knowledge of the management of the Company due to his prior service as the Company’s Chief Executive Officer.”

William "Trey" Martin, III departed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On October 18, 2022, Maravai LifeSciences Holdings, Inc. (the “Company”) placed William “Trey” Martin, III, Chief Executive Officer, on a paid leave of absence following the issuance of a temporary restraining order by the Delaware Court of Chancery preventing him from working for the Company pending further order of the Court in a lawsuit filed against him by his previous employer alleging violation of a noncompetition agreement.”

William "Trey" Martin, III was appointed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

“On September 30, 2022, William “Trey” Martin, III was appointed Chief Executive Officer of Maravai LifeSciences Holdings, Inc.”